Nanobodies and other single-domain antibodies for targeting misfolded proteins in neurodegenerative diseases and precision delivery to the central nervous system
Drug Delivery and Translational Research · 14.11.2026
DOI: 10.1007/s13346-026-02250-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 14.11.2026. Verfasst von Khanh D Nguyen und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Daegu, South Korea. Die Arbeit nennt 244 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Neurodegenerative diseases remain difficult to treat because pathological proteins must be recognized selectively within the central nervous system (CNS), which is poorly accessible to most biologics. Conventional antibodies have established the therapeutic value of targeting protein aggregates, but limited brain exposure, restricted access to intracellular targets, and fragment crystallizable (Fc)-dependent effects constrain their use. Nanobodies and other autonomous single-domain antibodies provide a compact, stable, and modular alternative capable of recognizing conformational or sterically restricted epitopes. This review relates aggregation inhibition, toxic-species attenuation, propagation interference and proteasomal, autophagic, or microglial clearance of amyloid-β, tau and α-synuclein to the CNS delivery requirements of single-domain antibody-based therapeutics. We then organize CNS delivery as three linked barriers, namely preservation of an intact construct in the circulation, productive blood–brain barrier transport, and postvascular distribution to the required extracellular, cellular or intracellular compartment. Multivalent and multispecific formats, half-life extension, receptor-mediated shuttles, cell-associated targeting and intracellular delivery modules are assessed in relation to the trade-offs introduced by greater molecular complexity. Integrating pathological-species recognition with a removal pathway and a quantitatively validated delivery design may convert single-domain antibodies from versatile binding reagents into controllable therapeutics for protein-misfolding neurodegenerative diseases. Graphical abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Daegu, South Korea.
- College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Daegu, South Korea. sypark20@kmu.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Nguyen, K. D., Nguyen, H., Tran, V. T., & Park, S. (2026). Nanobodies and other single-domain antibodies for targeting misfolded proteins in neurodegenerative diseases and precision delivery to the central nervous system. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-026-02250-2
Vancouver
Nguyen KD, Nguyen H, Tran VT, Park S. Nanobodies and other single-domain antibodies for targeting misfolded proteins in neurodegenerative diseases and precision delivery to the central nervous system. Drug Delivery and Translational Research. 2026. doi:10.1007/s13346-026-02250-2
BibTeX
@article{Nguyen2026,
author = {Nguyen, Khanh D and Nguyen, Hieu and Tran, Vi Thao and Park, Soyeun},
title = {Nanobodies and other single-domain antibodies for targeting misfolded proteins in neurodegenerative diseases and precision delivery to the central nervous system},
journal = {Drug Delivery and Translational Research},
year = {2026},
doi = {10.1007/s13346-026-02250-2}
}
EUVIMED